Innovation Pharmaceuticals Forms Irish Subsidiary to Facilitate International Development of Clinical Pipeline
February 26, 2019 10:10 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Feb. 26, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Companies...
Innovation Pharmaceuticals Receives New Patent for Compounds for Use in Treatment of Oral Mucositis
February 19, 2019 09:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent...
Innovation Pharmaceuticals Files Form 10-Q Quarterly Report
February 11, 2019 10:45 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announces that on February 8, 2019, it filed with...
Innovation Pharmaceuticals Establishing European Subsidiary; CEO Increases Equity Stake in IPIX
January 31, 2019 09:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, today announces that the Company is establishing a...
Innovation Pharmaceuticals Announces Clinical Development Plans for Oral Brilacidin for Inflammatory Bowel Disease
January 22, 2019 08:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 22, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce plans to initiate in 2019 a...
Innovation Pharmaceuticals Completes Gastric Fluid Testing of Brilacidin Supporting Development of an Oral Dosage Form to Treat Inflammatory Bowel Disease
January 14, 2019 08:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 14, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders the Company has...
Published Studies Confirm Cisplatin Remains Preferred Chemotherapy Component in Head and Neck Cancer Treatment; Innovation Pharmaceuticals on Target with Clinical Trials of Brilacidin for Preventing Severe Oral Mucositis
January 08, 2019 08:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 08, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to inform shareholders of recent...
Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate
January 02, 2019 09:00 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U.S. Patent &...
Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis
December 17, 2018 07:05 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company and the U.S. Food...
Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
November 13, 2018 07:30 ET
|
Innovation Pharmaceuticals, Inc.
BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is...